Theriva Biologics Inc
Research Theriva Biologics Inc (TOVX) on Bullrun: market cap USD 10.10M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTOVX
- ExchangeNYSE MKT
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 10.10M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 3.22M
- Free cash flow-USD 3.09M
Valuation Snapshot
latest market cap is USD 10.10M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 23.74M | -USD 16.70M | n/a | -2.08 | USD 13.06M | USD 1.67M | USD 15.38M |
| FY2024 | USD 0 | -USD 25.65M | -USD 16.94M | n/a | -19.03 | USD 11.61M | USD 92.00K | USD 19.07M |
| FY2023 | USD 0 | -USD 18.35M | -USD 19.20M | n/a | -28.48 | USD 23.18M | USD 225.00K | USD 36.96M |
| FY2022 | USD 0 | -USD 19.69M | -USD 19.20M | n/a | -1.31 | USD 41.79M | USD 278.00K | USD 51.83M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 10.10M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 7.49M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 4.87M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 7.33M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 7.13M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 35.65M | n/a | n/a | n/a |
About Theriva Biologics Inc
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Theriva Biologics Inc's market cap?
Theriva Biologics Inc's market capitalization is USD 10.10M.
What does Theriva Biologics Inc do?
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.